Abstract
As the ninth leading cause of death globally, diabetes mellitus (DM) is considered to be the worst chronic metabolic disease requiring an enormous need for healthcare with over 578 million expected cases by 2023. Several recent findings have demonstrated that mediating the activity of carbohydrate-hydrolyzing enzymes, including α-amylase and α-glucosidase, could be a potential strategy for managing the development of DM. In the presented study, a novel set of 1,3,5-trisubstituted-2-thioxoimidazolidin-4-ones was designed, synthesized, and characterized. The antidiabetic activity of the synthesized compounds was explored by assessing their inhibitory activity toward α-amylase and α-glucosidase enzymes. The results demonstrated that this class of compounds exhibits considerable inhibitory activity toward both α-amylase and α-glucosidase enzymes. Among the synthesized compounds, compound 5a demonstrated the most inhibitory activity with IC50 of 5.08 and µg/mL and 0.21 µg/mL toward α-glucosidase and α-amylase activities, respectively, as compared to the drug Acarbose (IC50 = 5.76 µg/mL and 0.39 µg/mL, respectively). To gain insights into the antidiabetic potential of compound 5a, we assessed the cytotoxic and antioxidant activities. Our findings indicated that compound 5a displays considerable cytotoxicity toward WI-38 cells with an IC50 of 88.54 µg/mL, as compared to the drug Celecoxib (IC50 = 93.05 µg/mL). Further, compound 5a exhibited a high scavenging activity toward 2,2-Diphenyl1-picrylhydrazyl (DPPH) free radicals (IC50 = 51.75 µg/mL) and showed a low potential to produce ROS as indicated by the monitoring of the generated H2O2 (132.4 pg/mL), as compared to Trolox (IC50 = 58.09 µg/mL) and Celecoxib (171.6 pg/mL). Finally, we performed extensive molecular modeling studies to affirm the binding affinity of this class of compounds to the binding pocket of α-amylase and α-glucosidase enzymes. Collectively, our findings indicate that this class of compounds, particularly compound 5a, could be utilized as a lead structure for the development of novel compounds with potential antidiabetic and antioxidant activities.
Funder
Faculty of Science, Port Said University
Suez Canal University, Egypt
Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
Faculty of Medicine, Al-Azhar University, Egypt
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference98 articles.
1. Epidemiology of Type 2 Diabetes—Global Burden of Disease and Forecasted Trends;Khan;J. Epidemiol. Glob. Health,2020
2. Insulin and Glucose-lowering Agents for Treating People with Diabetes and Chronic Kidney Disease;Lo;Cochrane Database Syst. Rev.,2018
3. Prevalence, Expenditures, and Complications of Multiple Chronic Conditions in the Elderly;Wolff;Arch. Intern. Med.,2002
4. Synthetic Heterocyclic Candidates as Promising α-Glucosidase Inhibitors: An Overview;Dhameja;Eur. J. Med. Chem.,2019
5. Khan, S., Khan, M., Rehman, W., Shah, M., Hussain, R., Rasheed, L., Khan, Y., Dera, A., Pashameah, R., and Alzahrani, E. (2022). Design, Synthesis, In Silico Testing, and In Vitro Evaluation of Thiazolidinone-Based Benzothiazole Derivatives as Inhibitors of α-Amylase and α-Glucosidase. Pharmaceuticals, 15.